Merck Says KEYTRUDA Plus Chemotherapy Showed Statistically Significant Improvement In pCR Rate As Neoadjuvant Therapy Versus Chemotherapy In High-Risk, Early-Stage ER+/HER2- Breast Cancer
Portfolio Pulse from Benzinga Newsdesk
Merck has announced that its drug KEYTRUDA, in combination with chemotherapy, has shown statistically significant improvement in pCR rate as neoadjuvant therapy versus chemotherapy alone in high-risk, early-stage ER+/HER2- breast cancer.
October 20, 2023 | 12:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Merck's KEYTRUDA has shown significant improvement in pCR rate in high-risk, early-stage ER+/HER2- breast cancer. This could potentially increase the demand for the drug, positively impacting Merck's stock.
The announcement of KEYTRUDA's effectiveness in treating high-risk, early-stage ER+/HER2- breast cancer could increase its demand, leading to higher revenues for Merck. This could potentially have a positive impact on Merck's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100